Treatment of refractory t-cell chronic lymphocytic leukemia with purine nucleoside analogues

Thomas Elmer Witzig, John J. Weitz, Joel H. Lundberg, Ayalew Tefferi

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

This report describes two cases of T-cell chronic lymphocytic leukemia (T-CLL) treated with purine nucleoside analogues. One patient had CD8+ CD3+ large granular lymphocytosis (LGL) producing transfusion-dependent anemia and was refractory to chemotherapy. Treatment with four cycles of fludarabine produced a clinical complete remission and a molecular genetic partial remission that has been durable for >15 months. The other patient had CD4+ T-prolymphocytic leukemia and was unresponsive to both fludarabine and 2-chlorodeoxy-adenosine. Further trials of these agents are warranted in T-CLL, especially the LGL variant.

Original languageEnglish (US)
Pages (from-to)137-139
Number of pages3
JournalLeukemia and Lymphoma
Volume14
Issue number1-2
DOIs
StatePublished - 1994

Fingerprint

Large Granular Lymphocytic Leukemia
T-Cell Prolymphocytic Leukemia
Purine Nucleosides
B-Cell Chronic Lymphocytic Leukemia
Prolymphocytic Leukemia
Refractory Anemia
Adenosine
Molecular Biology
Drug Therapy
Therapeutics
fludarabine

Keywords

  • Fludarabine
  • T-chronic lymphocytic leukemia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Treatment of refractory t-cell chronic lymphocytic leukemia with purine nucleoside analogues. / Witzig, Thomas Elmer; Weitz, John J.; Lundberg, Joel H.; Tefferi, Ayalew.

In: Leukemia and Lymphoma, Vol. 14, No. 1-2, 1994, p. 137-139.

Research output: Contribution to journalArticle

@article{102f10fc2c5b4378976e41c61a636e3c,
title = "Treatment of refractory t-cell chronic lymphocytic leukemia with purine nucleoside analogues",
abstract = "This report describes two cases of T-cell chronic lymphocytic leukemia (T-CLL) treated with purine nucleoside analogues. One patient had CD8+ CD3+ large granular lymphocytosis (LGL) producing transfusion-dependent anemia and was refractory to chemotherapy. Treatment with four cycles of fludarabine produced a clinical complete remission and a molecular genetic partial remission that has been durable for >15 months. The other patient had CD4+ T-prolymphocytic leukemia and was unresponsive to both fludarabine and 2-chlorodeoxy-adenosine. Further trials of these agents are warranted in T-CLL, especially the LGL variant.",
keywords = "Fludarabine, T-chronic lymphocytic leukemia",
author = "Witzig, {Thomas Elmer} and Weitz, {John J.} and Lundberg, {Joel H.} and Ayalew Tefferi",
year = "1994",
doi = "10.3109/10428199409049659",
language = "English (US)",
volume = "14",
pages = "137--139",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "1-2",

}

TY - JOUR

T1 - Treatment of refractory t-cell chronic lymphocytic leukemia with purine nucleoside analogues

AU - Witzig, Thomas Elmer

AU - Weitz, John J.

AU - Lundberg, Joel H.

AU - Tefferi, Ayalew

PY - 1994

Y1 - 1994

N2 - This report describes two cases of T-cell chronic lymphocytic leukemia (T-CLL) treated with purine nucleoside analogues. One patient had CD8+ CD3+ large granular lymphocytosis (LGL) producing transfusion-dependent anemia and was refractory to chemotherapy. Treatment with four cycles of fludarabine produced a clinical complete remission and a molecular genetic partial remission that has been durable for >15 months. The other patient had CD4+ T-prolymphocytic leukemia and was unresponsive to both fludarabine and 2-chlorodeoxy-adenosine. Further trials of these agents are warranted in T-CLL, especially the LGL variant.

AB - This report describes two cases of T-cell chronic lymphocytic leukemia (T-CLL) treated with purine nucleoside analogues. One patient had CD8+ CD3+ large granular lymphocytosis (LGL) producing transfusion-dependent anemia and was refractory to chemotherapy. Treatment with four cycles of fludarabine produced a clinical complete remission and a molecular genetic partial remission that has been durable for >15 months. The other patient had CD4+ T-prolymphocytic leukemia and was unresponsive to both fludarabine and 2-chlorodeoxy-adenosine. Further trials of these agents are warranted in T-CLL, especially the LGL variant.

KW - Fludarabine

KW - T-chronic lymphocytic leukemia

UR - http://www.scopus.com/inward/record.url?scp=0028228598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028228598&partnerID=8YFLogxK

U2 - 10.3109/10428199409049659

DO - 10.3109/10428199409049659

M3 - Article

C2 - 7920220

AN - SCOPUS:0028228598

VL - 14

SP - 137

EP - 139

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1-2

ER -